PRNewsWire
18 Oct 2025, 14:00 UTC · 48w ago
Verdict
Headline takes no side. We score BP −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The drug ivonescimab failed to demonstrate a statistically significant difference in overall survival in the Phase III HARMONi trial.
More negative than 99% of claims this week
Additional trial data indicated that ivonescimab produced weaker results in patients from North America and Europe than in other regions.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
Pomerantz LLP is investigating Summit Therapeutics for potential securities fraud or unlawful business practices related to these trial results.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is being investigated by a law firm on behalf of investors for potential claims.
More negative than 95% of ticker scores this week
The company is being investigated by a law firm on behalf of investors for potential claims.
More negative than 95% of ticker scores this week
The company is the subject of a securities fraud investigation following clinical trial failures and significant stock price drops.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
13h ago
+37.1%
Price is moving against the score
$45.42 vs $33.13 close before publication (Oct 17) · not market-adjusted
BP chart →
